Recruiting studies: Oropharyngeal P16Ink4A Negative Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascula
EARLY_Phase 1 · 1 location(s) · Emory University · NCT06914999 Oropharynx (OPX) Biomarker Trial
Phase N/A · 1 location(s) · Mayo Clinic · NCT06356272 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279 BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196 Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i
Phase 2 · 6 location(s) · National Cancer Institute (NCI) · NCT06980038 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head
Phase 2 · 676 location(s) · ECOG-ACRIN Cancer Research Group · NCT02734537 Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05172245 Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734 De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Phase 2 · 3 location(s) · Mayo Clinic · NCT05541016 TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433 Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT07156227 Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · 102 location(s) · National Cancer Institute (NCI) · NCT07195734 Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT06589804 A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Phase 2 · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT05544136 Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →